Clinical Trials
23 trialsNCT04729387 2026-06-04
Alpelisib Plus Olaparib in Platinum-resistant/Refractory, High-grade Serous Ovarian Cancer, With no Germline BRCA Mutation Detected
Novartis
Phase 3 Terminated
NCT02446600 2026-06-03
Testing the Use of A Single Drug (Olaparib) or the Combination of Two Drugs (Cediranib and Olaparib) Compared to the Usual Chemotherapy for Women With Platinum Sensitive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
National Cancer Institute (NCI)
Phase 3 Active not recruiting
NCT02345265 2026-05-28
Testing the Combination of the Study Drugs Cediranib and Olaparib in Recurrent Ovarian Cancer
National Cancer Institute (NCI)
Phase 2 Active not recruiting
NCT01081951 2026-05-13
Study to Compare the Efficacy and Safety of Olaparib When Given in Combination With Carboplatin and Paclitaxel, Compared With Carboplatin and Paclitaxel in Patients With Advanced Ovarian Cancer
AstraZeneca
Phase 2 Active not recruiting
NCT03740165 2026-05-04
KEYLYNK-001
Merck Sharp & Dohme LLC
Phase 3 Completed
NCT02502266 2026-04-29
Testing the Combination of Cediranib and Olaparib in Comparison to Each Drug Alone or Other Chemotherapy in Recurrent Platinum-Resistant Ovarian Cancer
National Cancer Institute (NCI)
Phase 2/3 Active not recruiting
NCT02734004 2026-04-20
MEDIOLA
AstraZeneca
Phase 1/2 Active not recruiting
NCT01844986 2025-12-10
SOLO-1
AstraZeneca
Phase 3 Active not recruiting
NCT01874353 2025-08-03
Olaparib Treatment in BRCA Mutated Ovarian Cancer Patients After Complete or Partial Response to Platinum Chemotherapy
AstraZeneca
Phase 3 Active not recruiting
NCT04330040 2025-03-10
SOLI
AstraZeneca
Phase 4 Completed
NCT00753545 2025-02-03
Assessment of Efficacy of AZD2281 in Platinum Sensitive Relapsed Serous Ovarian Cancer
AstraZeneca
Phase 2 Completed
NCT03314740 2025-01-10
BAROCCO
Mario Negri Institute for Pharmacological Research
Phase 2 Completed
NCT02953457 2024-11-19
Olaparib, Durvalumab, and Tremelimumab in Treating Patients With Recurrent or Refractory Ovarian, Fallopian Tube or Primary Peritoneal Cancer With BRCA1 or BRCA2 Mutation
Roswell Park Cancer Institute
Phase 2 Completed
NCT05258747 2024-10-03
A Crossover Bioequivalence Study of Olaparib Tablets, 150 mg (Lek Pharmaceuticals d.d.) and Lynparza® (Olaparib) Tablets 150 mg (AstraZeneca Pharmaceuticals LP), in Patients With Breast Cancer Gene (BRCA) Mutated Ovarian Cancer, Recurrent Ovarian Cancer or Metastatic Breast Cancer
Sandoz
Phase 1 Completed
NCT03402841 2024-08-21
OPINION
AstraZeneca
Phase 3 Completed
NCT04377087 2024-08-20
Delayed Initiation of Olaparib Maintenance Therapy in Platinum Sensitive Recurrent Ovarian Cancer
University of Pittsburgh
Phase 2 Terminated
NCT00679783 2023-07-12
Phase II Study of AZD2281 in Patients With Known BRCA Mutation Status or Recurrent High Grade Ovarian Cancer or Patients With Known BRCA Mutation Status/ Triple Neg Breast Cancer
AstraZeneca
Phase 2 Completed
NCT03106987 2022-10-07
OReO
AstraZeneca
Phase 3 Completed
NCT02282020 2022-07-26
SOLO3
AstraZeneca
Phase 3 Completed
NCT02983799 2022-04-13
Olaparib Tablets as a Treatment for Ovarian Cancer Subjects With Different HRD Tumor Status
AstraZeneca
Phase 2 Completed
NCT02889900 2022-03-08
CONCERTO
AstraZeneca
Phase 2 Completed
NCT00628251 2019-12-05
ICEBERG 3
AstraZeneca
Phase 2 Completed
NCT00494442 2018-08-01
ICEBERG 2
AstraZeneca
Phase 2 Completed